Jarislowsky Fraser Ltd decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 147,077 shares of the company’s stock after selling 4,124 shares during the period. Jarislowsky Fraser Ltd’s holdings in Novo Nordisk A/S were worth $7,081,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. Fisher Asset Management LLC boosted its stake in Novo Nordisk A/S by 3.7% during the third quarter. Fisher Asset Management LLC now owns 12,124,724 shares of the company’s stock valued at $583,806,000 after buying an additional 433,727 shares during the period. Folketrygdfondet boosted its stake in Novo Nordisk A/S by 13.2% during the second quarter. Folketrygdfondet now owns 6,914,192 shares of the company’s stock valued at $296,550,000 after buying an additional 803,608 shares during the period. Everett Harris & Co. CA boosted its stake in Novo Nordisk A/S by 0.3% during the second quarter. Everett Harris & Co. CA now owns 3,120,155 shares of the company’s stock valued at $133,823,000 after buying an additional 10,610 shares during the period. Northern Trust Corp lifted its stake in Novo Nordisk A/S by 0.5% during the second quarter. Northern Trust Corp now owns 1,975,217 shares of the company’s stock worth $84,717,000 after purchasing an additional 9,319 shares during the last quarter. Finally, NGAM Advisors L.P. lifted its stake in Novo Nordisk A/S by 3.0% during the second quarter. NGAM Advisors L.P. now owns 1,545,853 shares of the company’s stock worth $66,302,000 after purchasing an additional 44,948 shares during the last quarter. 6.01% of the stock is owned by institutional investors.
WARNING: “Novo Nordisk A/S (NVO) Shares Sold by Jarislowsky Fraser Ltd” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://transcriptdaily.com/2017/11/14/novo-nordisk-as-nvo-shares-sold-by-jarislowsky-fraser-ltd.html.
Shares of Novo Nordisk A/S (NVO) opened at $49.78 on Tuesday. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $50.95. The stock has a market capitalization of $127,270.50, a PE ratio of 21.80, a price-to-earnings-growth ratio of 2.98 and a beta of 0.63.
In related news, insider Eric S. Sprott acquired 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were purchased at an average price of $8.34 per share, for a total transaction of $417,000.00.
Several brokerages have issued reports on NVO. BidaskClub raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. BNP Paribas lowered Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Monday, September 25th. Zacks Investment Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Tuesday, October 10th. Finally, Bank of America Corporation raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, September 6th. Three analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $55.00.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.